MENS Advances Market Access for Botreso®, PCP After Positive Trials
Jyong Biotech Ltd. announced it has advanced market access strategies for its plant-based drugs, Botreso® and PCP, following analysis of their clinical efficacy and competitive advantages. Botreso® has completed four Phase III clinical trials, while PCP successfully completed its Phase II clinical trial, demonstrating significant differentiated advantages over synthetic drugs, including excellent safety, prostate cancer prevention potential, and metabolic benefits. The company believes its comprehensive approach and technological platform create high barriers to entry, positioning its products for premium pricing and international partnerships in a global BPH market projected to reach $9.8 billion by 2026.
Key Highlights
- Botreso® completed four Phase III clinical trials in the US and Taiwan.
- PCP successfully completed its Phase II clinical trial.
- No drug-related serious adverse events observed in 1-year (Botreso) or 2-year (PCP) trials.
- PCP Phase II trial showed a trend in reducing prostate cancer incidence.
- PCP reduced triglycerides (P=0.05), total cholesterol/LDL (P<0.05), and increased HDL (P<0.05).
- Global BPH drug market projected to reach $9.8 billion by 2026.
- On-patent BPH market potential exceeds $20 billion annually.
Price Impact
More from MENS